Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN84,7284,81,31
Msft0,01
Nokia3,5863,657-1,99
IBM-0,30
Mercedes-Benz Group AG53,0153,03-0,93
PFE-0,04
30.07.2025 0:30:00
Indexy online
AD Index online
select
AD Index online
 

  • 29.07.2025 21:21:01
AdaptimmTher Sp ADR (Frankfurt)
Poslední obchod Změna (%) Změna (EUR) Objem obchodů (EUR)
0,08 -32,77 -0,04 480
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 30.07.2025
Popis společnosti
Obecné informace
Název společnostiAdaptimmune Therapeutics PLC - ADR
TickerADAP
Kmenové akcie:ADR
RICADAP.O
ISIN-
Poslední známé roční výsledky31.12.2024
Poslední známé čtvrtletní výsledky31.03.2025
Počet zaměstnanců k 31.12.2024 506
Akcie v oběhu k 12.05.20251 590 309 546
MěnaUSD
Kontaktní informace
Ulice60 Jubilee Avenue, Milton Park
MěstoABINGDON
PSČOX14 4RX
ZeměUnited Kingdom
Kontatní osoba 
Funkce kontaktní osoby 
Telefon441 235 430 000

Business Summary: Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. The engineered T cell receptor (TCR) platform, which the Company is developing for personalized medicines designed to target and destroy difficult-to-treat solid tumor cancers. It is focused on the commercialization of TECELRA, which is a genetically modified autologous T-cell immunotherapy indicated for the treatment of adults with advanced synovial sarcoma. Its second T-cell immunotherapy, letetresgene autoleucel (lete-cel), targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). It has filed an IND for ADP-5701 for a Phase I trial in Head and Neck Cancer in collaboration with Galapagos NV (Galapagos). It has two pre-clinical programs for the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520).
Financial Summary: BRIEF: For the three months ended 31 March 2025, Adaptimmune Therapeutics PLC - ADR revenues increased 28% to $7.3M. Net loss decreased 2% to $47.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Clinical-stage biopharmaceutical segment loss decrease of 7% to $45.7M. Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.03.
Odvětvová klasifikace
TRBC2012Biopharmaceuticals
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research



  • Poslední aktualizace: 30.07.2025
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chief Executive Officer, DirectorAdrian Rawcliffe5201.09.2019
Chief Financial OfficerGavin Wood5501.04.202001.04.2020
Chief Operating OfficerWilliam Bertrand6015.03.201715.03.2017
Chief Scientific OfficerJoanna Brewer4904.05.202204.05.2022
Chief Patient Supply OfficerJohn Lunger5601.08.201901.08.2019
Chief Medical OfficerElliot Norry6213.01.2020
Chief Commercial OfficerCintia Piccina5218.03.202431.01.2022